Tamoxifen Can Cause Aggressive Cancer Tumours August 29, 2009Posted by Dreamhealer in Big Pharma, Breast Cancer.
Long-term users of cancer prevention drug Tamoxifen it is reported, could develop rare cancers from taking it, since it is the drug of choice, prescribed after the detection of breast cancer or surgery. This is disturbing news for healthgivers and breast cancer survivors, many of whom are long term users of tamoxifen, with a 20% success rate in preventing further incidences of cancer.Tamoxifen, which is the most prescribed and oldest selective estrogen receptor modulator (SERM) prescribed for women with breast cancer and rare but aggressive tumours, as it is known to block estrogen receptors in the breast, inhibiting their growth. Which is why, tamoxifen so successful in preventing a recurrence of common breast tumours, and while it has come under scrutiny of late, some suggest the risks still outweigh the downside.The journal Cancer Research reports a study of 1100-women with estrogen sensitive tumours. Women who took tamoxifen for 5-years, there was a 60% less risk of a recurrence of estrogen sensitive breast cancer. Though, they were four times more likely to develop rare and extremely aggressive breast cancer that was not estrogen sensitive, rendering Tamoxifen ineffective.The medical community, in its typical reaction to bad news, has begun to question the report and its methodology, and it is especially bad news, because tamoxifen is used as the frontline defence in the fight against cancer.The report published in Cancer Research, is not based on any research study, rather only on observation made by the esteemed Fred Hutchinson Cancer Research Centre, Seattle, WA, which has long been known for comprehensive scientific research and reporting.According to Dr. Li, the author of the report, long term tamoxifen usage increases a four-fold risk for a more aggressive, difficult-to-treat cancer type in the opposite breast or contralateral, to the initial tumour.The current report is pursuant to Dr. Li’s previously published findings in 2001, which study of 9,000-women over the age of 50 followed from 1990 and 1999, reported the same findings i. e. a five-fold increased risk of estrogen-receptor (ER)-negative breast cancers in breast cancer survivors taking tamoxifen.Tamoxifen use has been seen to reduce ER-positive contralateral breast cancers, which is the most common type of cancer, found in two-thirds of the cases diagnosed by 20%. With new findings showing a 500% increase in estrogen-receptor (ER)-negative breast cancers, breast cancer survivors and caregivers need to assess risks vs. benefits, including looking for alternative treatments.New homeopathy and botanical medicine research looks promising for both cancer prevention and cancer relapse, minus side effects triggered by tamoxifen and other drugs.
Submitted by: Anna Tomova